FDA Bars Tyler Jordan Hall from Drug Imports After Conviction
Published Date: 1/23/2026
Notice
Summary
Tyler Jordan Hall is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of bringing in unapproved drugs. He didn’t respond to the FDA’s notice, so the ban starts January 23, 2026, and he can apply to end it anytime. This means no drug imports from him for a while, keeping the market safer and cleaner!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Five-Year Import Ban on Named Importer
The FDA debarred Tyler Jordan Hall for 5 years, effective January 23, 2026, prohibiting him from importing or offering for import any drug into the United States. The order also makes importing any drug by, with the assistance of, or at the direction of Mr. Hall a prohibited act.
Right to Apply to End Debarment Anytime
Mr. Hall may apply at any time to terminate his debarment under section 306(d)(1) of the FD&C Act. Applications may be submitted electronically at https://www.regulations.gov (Docket No. FDA-2025-N-1331) or as written/paper submissions to the Dockets Management Staff with options to mark confidential information as described in the order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17401, Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that CABAZITAXEL (cabazitaxel) solution (injection), 60 milligrams (mg)/6 milliliters (mL) (10 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for Cabazitaxel (cabazitaxel) solution (injection), 60 mg/6 mL (10 mg/mL), if all other legal and regulatory requirements are met.
2026-17380, International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
The FDA is asking the public to share their thoughts on eight drugs that might get new international rules to control their use and abuse. This affects doctors, patients, and drug makers because it could change how these drugs are used medically or restricted worldwide. Comments are open until September 3, 2026, so jump in and have your say before the deadline!
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2026-01295, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Regional Economic Development Data Collection Instrument
The Department of Commerce wants your thoughts on a new survey that helps track how regions grow their economies. This affects communities and businesses that work with the Economic Development Administration, and your feedback is needed by March 24, 2026. The goal is to keep the survey helpful but easy to fill out, with no extra costs for participants.
Next: 2026-01297, Application for Authorization To Export Electric Energy; Electric Power Markets USA, LLC
Electric Power Markets USA, LLC wants permission to send electricity from the U.S. to Mexico for the next five years. This affects energy buyers and sellers in Texas and could boost cross-border power trade without hurting U.S. electricity supplies. If you have thoughts or concerns, you’ve got until February 23, 2026, to speak up!